Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development. Vincent J. Milano, President and Chief Executive Officer of Idera Pharmaceuticals, stated, “We are delighted to welcome Clayton to Idera. His business acumen and strategic insight forged over 25 years in the biopharmaceutical industry will significantly enhance our abili… Read more »
Shares of Idera Pharmaceuticals opened today at $4.67 . IDRA has a 1-year high of $6.87 and a 1-year low of $1.94. The stock’s 50-day moving average is $4.42 and it’s 200-day moving average is $3.03.
On the ratings front, Idera Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on December 17, Piper Jaffray analyst Edward Tenthoff reiterated a Buy rating on IDRA, with a price target of $7, which implies an upside of 49.9% from current levels. Separately, on December 9, Cowen`s Boris Peaker maintained a Buy rating on the stock .
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.